Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Clin Cancer Res. 2013 Feb 5;19(7):1729–1739. doi: 10.1158/1078-0432.CCR-12-1907

Figure 5. Plasma components do not alter sensitivity to JAK2 inhibitor.

Figure 5

Effect of plasma components on response to CYT387 (panels A–C) or INCB18424 (panels D–F) as measured by STAT5 phosphorylation and presented as MFI. Peripheral blood cells from two MF patients (2521, panel A and 2517, panel B) were treated ex vivo with GM-CSF in the presence or absence of CYT387, as whole, unperturbed blood (WB), as plasma-depleted blood reconstituted with native plasma (e.g. 2521+2521) or with PV patient (2518) plasma of equivalent volume (e.g. 2521+2518). Likewise, PV peripheral blood was exposed to CYT387 (panel C) or INCB18424 (panel F) as whole blood, native reconstituted blood, or with plasma from either MF patient (2518+2517 and 2518+2521). MF blood cells (2517, panel D and 2521, panel E) were treated with GM-CSF +/− INCB18424 in native plasma or PV plasma.